SCYNEXIS Reports Q2 2026 Financial Results with Revenue Decline and Net Income Turnaround

SCYNEXIS, Inc. reported its financial results for the second quarter of 2026, revealing a significant shift in its revenue and expenses compared to the same period in 2025. The company generated $235,000 in license agreement revenue, a decrease of 82.8% from $1.36 million in the prior year. This decline is attributed to the reduced revenue from its licensing agreement with GlaxoSmithKline, which has been a key revenue source for the company. Total operating expenses for the quarter were $8.01 million, down 26.7% from $10.93 million in the previous year, primarily due to a 45.5% reduction in research and development costs, which fell to $3.89 million from $7.14 million.

In terms of profitability, SCYNEXIS reported a net income of $7.4 million for the quarter, a notable improvement from a net loss of $6.89 million in the same quarter of 2025. This turnaround was largely driven by a $14.15 million gain from the fair value adjustment of warrant liabilities, reflecting changes in the company's stock price. The company’s accumulated deficit increased to $399 million as of June 30, 2026, compared to $385 million at the end of 2025.

Strategically, SCYNEXIS made significant advancements, including the acquisition of the SCY-770 program from Poxel SA, which is aimed at treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company paid an upfront fee of $8 million for this asset, which is expected to enhance its pipeline and address a significant unmet medical need in rare diseases. Additionally, SCYNEXIS completed a private placement in March 2026, raising $40 million to support its ongoing development efforts, which is expected to fund operations into 2029.

Operationally, SCYNEXIS has seen changes in its employee headcount and organizational structure, although specific figures were not disclosed in the filing. The company has also undergone a reverse stock split, effective May 29, 2026, to comply with Nasdaq listing requirements, reducing the number of outstanding shares from approximately 79.5 million to about 9.9 million. This move was part of a broader strategy to enhance its market position and ensure compliance with exchange regulations.

Looking ahead, SCYNEXIS anticipates continuing its development of SCY-770 and SCY-247, with plans to initiate a Phase 2 clinical study for SCY-770 in ADPKD patients by the end of 2026. The company believes that its current cash and investment resources, totaling $71.1 million, will be sufficient to support its operations for at least the next 12 months, although it acknowledges the need for additional capital to fund ongoing research and development activities.